Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › IL › Oak Lawn › NPI 1902911050
Physician

Rawda, Ayman

Rawda, Ayman was paid $15.08M by Medicaid between Jan 2018 and Dec 2024, across 104 billing codes. Its largest line is 87633, Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets — 24% of everything it billed.

33Billing provider infoRAWDA, AYMAN
OAK LAWN, IL 60453
33aNPI1902911050assigned 08/20/2006
33bProvider typePediatrics Physician
28Total paid$15.08M
24GClaims336,744
24DCodes billed104
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers

Next to other Pediatrics Physician providers in Illinois

Rank by total paid#1 of 1,805
Median peer was paid$55K
This provider vs. median273×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

$0$200K$400K$600K2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
201826,360$800K
201956,842$1.51M
202031,918$835K
202152,438$2.72M
202268,059$3.96M
202357,064$2.80M
2024incomplete44,063$2.46M
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
87633 Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets 24% 12,608 11,210 $3.69M
0202U Oncology (prostate), multianalyte, gene expression profiling 19% 12,176 10,719 $2.94M
99213 Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity 17% 53,704 41,493 $2.58M
99214 Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 9.8% 20,153 14,711 $1.47M
99392 Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) 3.4% 6,976 5,279 $520K
99393 Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) 2.9% 5,879 4,631 $431K
87880 Infectious agent antigen detection by immunoassay; Streptococcus, group A 2.8% 27,377 22,198 $423K
99203 Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity 2.7% 8,940 7,874 $413K
99391 Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) 2.3% 5,161 4,073 $345K
96110 Developmental screening, with scoring and documentation, per standardized instrument 1.5% 12,555 10,225 $229K
99394 Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) 1.5% 2,847 2,295 $227K
99204 Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity 1.4% 2,994 2,365 $217K
92 more codes
99381 <1% 1,100 $92K
94760 <1% 36,162 $86K
87804 Infectious agent antigen detection by immunoassay; Influenza, each type <1% 4,202 $79K
92587 <1% 6,423 $78K
90670 <1% 4,028 $70K
96127 <1% 6,967 $69K
D1206 Topical application of fluoride varnish <1% 2,643 $65K
99212 Office or other outpatient visit for the evaluation and management of an established patient, straightforward <1% 2,515 $63K
99383 <1% 709 $62K
95004 Percutaneous tests with allergenic extracts, immediate type reaction <1% 1,157 $61K
99000 <1% 2,438 $46K
90648 <1% 3,414 $34K
99215 Doctor's office visit, returning patient (complex) <1% 661 $33K
83655 <1% 2,733 $32K
90633 <1% 3,420 $31K
96160 <1% 2,354 $30K
99211 Office or other outpatient visit for the evaluation and management of an established patient, minimal severity <1% 2,526 $29K
87637 Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV <1% 216 $29K
94640 Pressurized or nonpressurized inhalation treatment for acute airway obstruction <1% 2,035 $29K
99202 Office or other outpatient visit for the evaluation and management of a new patient, straightforward <1% 883 $28K
81002 <1% 10,241 $26K
90710 <1% 2,238 $25K
99382 <1% 292 $25K
90723 <1% 2,330 $24K
90651 <1% 1,765 $23K
90680 <1% 2,202 $23K
90686 <1% 2,392 $23K
96372 Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular <1% 2,245 $22K
99384 <1% 206 $20K
92551 <1% 1,280 $19K
90734 <1% 1,743 $18K
90700 <1% 1,888 $18K
36416 <1% 4,186 $16K
90716 <1% 1,264 $15K
90696 <1% 1,518 $14K
71046 Radiologic examination, chest; 2 views <1% 830 $14K
90698 <1% 1,283 $13K
93000 <1% 638 $13K
0241U Neonatal screening for hereditary disorders, genomic sequence analysis panel <1% 130 $13K
90715 <1% 1,257 $13K
99460 <1% 196 $12K
90707 <1% 1,064 $11K
85018 <1% 4,971 $11K
90744 <1% 1,187 $10K
0071A <1% 247 $10K
99173 <1% 1,219 $9K
0072A <1% 238 $9K
99238 Hospital discharge day management, 30 minutes or less <1% 184 $9K
69210 <1% 374 $8K
90713 <1% 616 $6K
99174 <1% 836 $6K
0001A <1% 143 $6K
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe <1% 116 $6K
0002A <1% 134 $5K
87631 <1% 48 $5K
86769 <1% 116 $5K
94664 <1% 354 $5K
87651 Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe <1% 96 $4K
96360 Intravenous infusion, hydration; initial, 31 minutes to 1 hour <1% 202 $4K
90681 <1% 262 $3K
J0696 Injection, ceftriaxone sodium, per 250 mg <1% 1,496 $3K
90620 <1% 200 $2K
92558 <1% 187 $2K
90685 <1% 327 $2K
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r <1% 24 $2K
90460 Immunization administration through 18 years of age via any route, first or only component <1% 8,086 $1K
87807 <1% 128 $1K
96374 Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance <1% 37 $1K
74018 <1% 64 $1K
90621 <1% 78 $1K
69209 <1% 139 $923.00
99072 <1% 5,718 $812.50
36415 Collection of venous blood by venipuncture <1% 199 $754.29
93005 Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report <1% 73 $536.28
96361 Intravenous infusion, hydration; each additional hour <1% 28 $515.97
96365 Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour <1% 28 $496.86
96367 <1% 23 $429.98
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 <1% 16 $400.00
86580 <1% 99 $384.00
J1100 Injection, dexamethasone sodium phosphate, 1 mg <1% 452 $281.22
90461 <1% 5,343 $172.00
92550 <1% 14 $163.10
J7613 Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg <1% 915 $92.13
J7030 Infusion, normal saline solution , 1000 cc <1% 43 $29.70
J2405 Injection, ondansetron hydrochloride, per 1 mg <1% 124 $27.40
J7620 Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme <1% 134 $18.13
96161 <1% 421 $2.91
99051 <1% 1,611 $2.77
99188 0% 19 $0.00
90472 Immunization administration, each additional vaccine (list separately) 0% 19 $0.00
G9903 Patient screened for tobacco use and identified as a tobacco non-user 0% 155 $0.00
90471 Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine 0% 57 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.